Evidence map›Paper›PMID 36500607›Full record

ArticleMolecules (Basel, Switzerland)2022

Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAF

Elisabetta Marini, Marco Marino, Giulia Gionfriddo, Federica Maione, Marta Pandini, Daniele Oddo, Marta Giorgis, Barbara Rolando, Federica Blua, Simone Gastaldi and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. FDA-approved kinase inhibitors in PROTAC design, development and synthesis.Journal of enzyme inhibition and medicinal chemistry · 2025
    Review
  3. BRAFClinical and translational medicine · 2025
    Article
  4. STK11 mutation affects tumor proliferation by impacting CD4Central-European journal of immunology · 2024
    Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Elisabetta MariniDepartment of Drug Science and Technology, University of Turin, 10125 Torino, Italy.ORCID 0000-0002-3638-5219
Marco MarinoDepartment of Drug Science and Technology, University of Turin, 10125 Torino, Italy.
Giulia GionfriddoCandiolo Cancer Institute, FPO-IRCCS (Fondazione del Piemonte per l'Oncologia-Istituti di Ricovero e Cura a Carattere Scientifico), 10060 Candiolo, Italy.
Federica MaioneCandiolo Cancer Institute, FPO-IRCCS (Fondazione del Piemonte per l'Oncologia-Istituti di Ricovero e Cura a Carattere Scientifico), 10060 Candiolo, Italy.
Marta PandiniCandiolo Cancer Institute, FPO-IRCCS (Fondazione del Piemonte per l'Oncologia-Istituti di Ricovero e Cura a Carattere Scientifico), 10060 Candiolo, Italy.ORCID 0000-0002-6235-3181
Daniele OddoCandiolo Cancer Institute, FPO-IRCCS (Fondazione del Piemonte per l'Oncologia-Istituti di Ricovero e Cura a Carattere Scientifico), 10060 Candiolo, Italy.ORCID 0000-0001-6179-1668
Marta GiorgisDepartment of Drug Science and Technology, University of Turin, 10125 Torino, Italy.ORCID 0000-0002-3282-1220
Barbara RolandoDepartment of Drug Science and Technology, University of Turin, 10125 Torino, Italy.ORCID 0000-0001-6138-1503
Federica BluaDepartment of Drug Science and Technology, University of Turin, 10125 Torino, Italy.ORCID 0000-0002-0306-9543
Simone GastaldiDepartment of Drug Science and Technology, University of Turin, 10125 Torino, Italy.ORCID 0000-0003-0487-3266
Serena MarchiòCandiolo Cancer Institute, FPO-IRCCS (Fondazione del Piemonte per l'Oncologia-Istituti di Ricovero e Cura a Carattere Scientifico), 10060 Candiolo, Italy.ORCID 0000-0001-8214-0776
Sandra KovachkaDepartment of Drug Science and Technology, University of Turin, 10125 Torino, Italy.
Francesca SpyrakisDepartment of Drug Science and Technology, University of Turin, 10125 Torino, Italy.ORCID 0000-0002-4016-227X
Eleonora GianquintoDepartment of Drug Science and Technology, University of Turin, 10125 Torino, Italy.
Federica Di NicolantonioCandiolo Cancer Institute, FPO-IRCCS (Fondazione del Piemonte per l'Oncologia-Istituti di Ricovero e Cura a Carattere Scientifico), 10060 Candiolo, Italy.ORCID 0000-0001-9618-2010
Massimo BertinariaDepartment of Drug Science and Technology, University of Turin, 10125 Torino, Italy.ORCID 0000-0002-2533-5830
University of Turin · ITCandiolo Cancer Institute · ITUniversité Côte d'Azur · FR

Funding

Fondazione Piemontese per la Ricerca sul Cancro Onlus 5 x milleItalian Association for Cancer Research ID21091Ministero della Salute Ricerca corrente 2022
6 · The paper itself

Abstract

BRAF is a serine/threonine kinase frequently mutated in human cancers. BRAF

Indexed as

Proteolysis Targeting ChimeraProto-Oncogene Proteins B-rafCarbamatesCell Line, TumorHumansMutationProtein Kinase InhibitorsSulfonamidesBRAF protein, humanCarbamatesencorafenibProtein Kinase InhibitorsProteolysis Targeting ChimeraProto-Oncogene Proteins B-rafSulfonamidesBRAF kinaseencorafenibmolecular dynamicspomalidomidePROTACs

Identifiers

PMID36500607
PMCPMC9736157
OpenAlexW4311532769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.